Latest News

Explore the long-term efficacy of biologics for HS, highlighting bimekizumab's superior outcomes in managing this chronic condition.

Galderma's relabotulinumtoxinA (Relfydess) aims to revolutionize wrinkle treatments with rapid results and lasting effects, pending FDA approval.

Arcutis reveals promising phase 2 results for roflumilast cream in infants with AD, highlighting safety and potential efficacy.

Explore top dermatology conferences and meetings in February 2026 and let us know which ones you'll be attending!

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

In case you missed it, this week we had news on the FDA's breakthrough designation of litifilimab for CLE, data on bitopertin in EPP treatment, the role of icotrokinra in the psoriasis landscape, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Kyowa Kirin takes full control of rocatinlimab, aiming to address unmet needs in atopic dermatitis while ensuring continuity in clinical trials.

Icotrokinra emerges as a groundbreaking oral treatment for moderate-to-severe psoriasis, showing superior efficacy compared to existing therapies at Maui Derm 2026.

Jennelle Daly, PA-C, explores the integration of aesthetic dermatology and wellness, emphasizing holistic approaches for optimal skin health and patient outcomes.

Explore the top headlines of the month, including insights on regulatory updates, expert pearls, and more.

A phase 2 trial reveals soficitinib's potential to significantly improve symptoms and quality of life in patients with moderate to severe AD.